問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
林俊余
下載
2021-03-15 - 2025-12-31
Condition/Disease
Test Drug
Participate Sites7Sites
Recruiting6Sites
Terminated1Sites
2023-12-22 - 2030-10-25
Participate Sites4Sites
Recruiting4Sites
2020-12-01 - 2024-05-17
Participate Sites3Sites
Recruiting3Sites
2025-10-01 - 2027-09-30
2021-06-17 - 2021-12-31
The pathological diagnosis is confirmed as rectal adenocarcinoma, T3~T4, N any, M0 .The distal boundary of the tumor to the anal opening must be less than or equal to 10 cm.
PEP503
全部
